Market Research Industry Reports

NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H1 2018

Summary

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - NAD-dependent deacetylase sirtuin-1 is a protein encoded by the SIRT1 gene. It modulates chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. It is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT).

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) pipeline Target constitutes close to 10 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 2 and 2 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Cardiovascular, Central Nervous System, Infectious Disease and Respiratory which include indications Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Obesity, Type 2 Diabetes, Atherosclerosis, Bacterial Pneumonia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Ewing Sarcoma, Parkinsons Disease, Peritonitis and Solid Tumor.

The latest report NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H1 2018, outlays comprehensive information on the NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)
- The report reviews NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics and enlists all their major and minor projects
- The report assesses NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope


List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Overview 6
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Companies Involved in Therapeutics Development 19
Bial - Portela & Ca SA 19
GlaxoSmithKline Plc 19
Jyant Technologies Inc 19
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Drug Profiles 21
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
(leucine + metformin hydrochloride) - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
(leucine + sildenafil citrate) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
BIA-6512 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
resveratrol - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
resveratrol - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules to Inhibit SIRT1 for Chronic Myelogenous Leukemia - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
SRT-3025 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
toxoflavin - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Dormant Products 34
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Discontinued Products 36
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Product Development Milestones 37
Featured News & Press Releases 37
Jun 10, 2016: NuSirt Biopharma Presenting New Research at American Diabetes Associations 76th Annual Scientific Sessions 37
Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Associations 76th Annual Scientific Sessions 37
May 18, 2016: NuSirt Biopharma to Present at American Diabetes Associations 76th Scientific Sessions 38
Jan 26, 2016: Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes 38
Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment 39
Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease 39
Jun 25, 2015: New Study: NuSirt Technology Demonstrates Potential as New Type 2 Diabetes Therapy 40
Jun 06, 2015: NuSirt Biopharma Presenting New Data On Leucine-Metformin Combination at American Diabetes Association 75th Scientific Sessions 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018 7
Number of Products under Development by Therapy Areas, H1 2018 8
Number of Products under Development by Indication, H1 2018 9
Number of Products under Development by Companies, H1 2018 10
Products under Development by Companies, H1 2018 11
Number of Products under Investigation by Universities/Institutes, H1 2018 12
Products under Investigation by Universities/Institutes, H1 2018 13
Number of Products by Stage and Mechanism of Actions, H1 2018 15
Number of Products by Stage and Route of Administration, H1 2018 17
Number of Products by Stage and Molecule Type, H1 2018 18
Pipeline by Bial - Portela & Ca SA, H1 2018 19
Pipeline by GlaxoSmithKline Plc, H1 2018 19
Pipeline by Jyant Technologies Inc, H1 2018 20
Dormant Products, H1 2018 34
Dormant Products, H1 2018 (Contd..1), H1 2018 35
Discontinued Products, H1 2018 36

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018 7
Number of Products under Development by Therapy Areas, H1 2018 8
Number of Products under Development by Top 10 Indications, H1 2018 9
Number of Products by Mechanism of Actions, H1 2018 14
Number of Products by Stage and Mechanism of Actions, H1 2018 14
Number of Products by Routes of Administration, H1 2018 16
Number of Products by Stage and Routes of Administration, H1 2018 16
Number of Products by Stage and Molecule Type, H1 2018 18

Construction in Canada – Key Trends and Opportunities to 2022

SynopsisFollowing two years of contraction, the Canadian construction industry rebounded in 2017, and registered an annual growth of 3.1% in real terms. This momentum is expected to continue in 2018,

USD 1950View Report

2018 Canada Nucleic Acid Testing (NAT) Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the molecular diagnostics market during the next five years.Highlights- Five-year test

USD 4250View Report

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H2 2017

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H2 2017NAD

USD 3500View Report

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H1 2017

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H1 2017According

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 3500
  • Site Licence    USD 7000
  • Enterprise Wide Licence    USD 10500
$ 3500

Reports Details

Published Date : May 2018
No. of Pages :44
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube